ZRC-3308 / Zydus Lifesciences - LARVOL DELTA

ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection. (PubMed, Viruses) - "The mAb cocktail demonstrated effective prophylactic and therapeutic activity against SARS-CoV-2 infection in Syrian hamsters. The antibody cocktail appears to be a promising candidate for prophylactic use and for therapy in early COVID-19 cases that have not progressed to severe disease."

Clinical • Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Zydus gets nod for trials of antibodies cocktail to treat Covid-19: Report (Business Standard) - "The only Indian company Zydus Cadila which claims to have developed neutralising monoclonal antibodies (mAbs)-based cocktail for the treatment of COVID-19 has been given permission to conduct clinical trials by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO)...'SEC gives a recommendation for the Phase I and II clinical trials of Zydus Cadila's biological therapy ZRC-3308...'"

New P1 trial • New P2 trial • Infectious Disease • Novel Coronavirus Disease

Zydus seeks DCGI approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise COVID infection (Equitybulls) - "ZRC-3308 is a cocktail of two monoclonal antibodies targeting two unique epitopes on the spike protein of SARSCoV-2....ZRC-3308 has demonstrated the ability to neutralize SARS-CoV-2 both in vitro and in animal studies. In animal studies ZRC-3308 reduced damage to the lungs in both prophylactic and therapeutic settings. ZRC-3308 has been found to be safe and well tolerated in animal toxicology studies. Zydus is currently seeking permission to initiate phase 1/3 human clinical trials from the DCGI."

New P1 trial • New P3 trial • Preclinical • Infectious Disease • Novel Coronavirus Disease